DEF: GRAIL, Inc. Announces 2025 Annual Meeting of Stockholders, Highlights Progress Since Illumina Separation

GRAIL, Inc. reports strong growth for Galleri in 2024, progress in regulatory efforts, improved cost efficiency, and a new test version rollout, following its separation from Illumina.

Summary

• GRAIL, Inc. held its 2025 Annual Meeting of Stockholders on May 29, 2025.
• The company separated from Illumina and began publicly trading in June 2024.
• In 2024, GRAIL sold over 137,000 tests and achieved a 45% increase in U.S. Galleri revenue compared to 2023.
• The company completed final study visits for the NHS-Galleri study and PATHFINDER 2 in 2024.
• GRAIL anticipates completing its PMA filing in the first half of 2026.
• A significant restructure was implemented in the second half of 2024 to extend the capital runway into 2028.
• GRAIL began transitioning to an updated Galleri test with an automated and integrated workflow in late 2024.
• The company is seeking FDA product approval and reimbursement for its Galleri test.
• William (Bill) Chase was elected as a Class I Director to serve until the 2028 Annual Meeting.
• Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Sentiment

Score: 7

Explanation: The document expresses a positive outlook, highlighting growth in revenue and progress in regulatory efforts. However, it also acknowledges the challenges and risks associated with obtaining FDA approval and reimbursement, as well as the ongoing commercial agreements with Illumina.

Positives

• GRAIL achieved a 45% increase in U.S. Galleri revenue in 2024 compared to 2023.
• The company completed final study visits for its two registrational studies, NHS-Galleri and PATHFINDER 2.
• A restructure was implemented to extend the capital runway into 2028.
• GRAIL is transitioning to an updated Galleri test leveraging an automated and integrated workflow.
• The company believes it is in a strong financial position.

Risks

• The company's future success depends on obtaining FDA approval and reimbursement for the Galleri test.
• The company faces risks related to compliance with Section 355 of the Code, which may limit its ability to pursue strategic transactions.
• The company's ongoing commercial agreements with Illumina, including the royalty payment obligations, could impact its financial performance.

Future Outlook

GRAIL is looking to a future where it can detect more cancers through screening before symptoms arise, enabling more effective treatments and reducing costs of care. The company anticipates completing its PMA filing in the first half of 2026 and believes it is in a strong financial position.

Management Comments

• 2024 was a transformative year for GRAIL as we separated from Illumina and began publicly trading in June.
• We've seen strong growth for Galleri in a largely pre-reimbursement environment, progressed our regulatory efforts, improved our cost efficiency, and recently rolled out a new version of the test, preparing us for scalability.
• We are building on our clinical evidence program, as we look towards a future where we can detect more cancers through screening, before symptoms arise.
• We believe we are in a strong financial position, and are pleased with the momentum we are seeing as we continue to drive multi-cancer early detection from an idea towards becoming a new standard of care alongside existing cancer screenings.

Industry Context

GRAIL is positioning itself as an early leader in the multi-cancer early detection field, establishing relationships within the cancer and primary care communities and collaborating with academic and community medical centers, opinion leaders, policy, and advocacy groups.

Related Party Transactions

• The company is party to various agreements with Illumina and its subsidiaries, including a supply and commercialization agreement and license agreements.
• Illumina is a customer of the Company, and purchased $460 thousand and $652 thousand of Galleri tests from us in 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders are asked to vote on the election of a director and the ratification of the appointment of an independent registered public accounting firm.
• The company's progress in developing and commercializing its Galleri test has the potential to improve cancer detection and treatment outcomes for patients.
• Employees are impacted by the company's compensation and benefit plans, as well as the ongoing relationship with Illumina.

Next Steps

• Complete PMA filing in the first half of 2026.
• Continue to drive multi-cancer early detection towards becoming a new standard of care.
• Continue to make progress towards FDA product approval and reimbursement.

Key Dates

Keywords

GRAIL, Galleri, Illumina, Annual Meeting, FDA, PMA filing, Cancer detection, Early detection, Stockholders, Revenue, Clinical studies, Directors, Audit firm